In chronic myeloid leukemia, the identification of individual BCR-ABL1 fusions is required for the development of personalized medicine approach for minimal residual disease monitoring at the DNA level. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.